Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 5, 2013, Pages 460-465

  Maher, Toby M ^a,b,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Biomarkers; Genomics; Interstitial lung disease; Transcriptomics; Usual interstitial pneumonia

Indexed keywords

CHEMOKINE; CHEMOKINE CCL18; MATRILYSIN; MUCIN 5B; UNCLASSIFIED DRUG;

DISEASE SEVERITY; FATALITY; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; PATHOGENESIS; PHENOTYPE; PROGNOSIS; REVIEW; SURVIVAL; SYSTEMS BIOLOGY; TRANSCRIPTOMICS;

GENE EXPRESSION PROFILING; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCIN-5B; POLYMORPHISM, GENETIC; PROGNOSIS; PROTEOMICS; SEVERITY OF ILLNESS INDEX; SYSTEMS BIOLOGY;

EID: 84881639762     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328363f4b7     Document Type: Review

References (53)

1. Maher TM. Idiopathic pulmonary fibrosis: Pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33:69-83
2. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66:462-467
3. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174:810-816
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement; idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183:788-824
5. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis.AmJ Respir Crit Care Med 2011; 183:431-440
6. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377:1760-1769
7. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176:636-643
8. Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008; 76:288-294
9. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161:5-8
10. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: Multiple causes and multiple mechanisms? Eur Respir J 2007; 30:835-839
11. Sauer U, Heinemann M, Zamboni N. Genetics. Getting closer to the whole picture. Science 2007; 316:550-551
12. Trusheim MR, Burgess B, Hu SX, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011; 10:817-833
13. Tsai HP, Chen SC, Chien HT, et al. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer. World J Surg Oncol 2012; 10:42
14. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1:493-502
15. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
16. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-1098
17. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic model research. PLoS Med 2013; 10:e1001381
18. Riley RD, Hayden JA, Steyerberg EW, et al. Prognosis Research Strategy (PROGRESS) 2: Prognostic factor research. PLoS Med 2013; 10:e1001380
19. Hingorani AD, Windt DA, Riley RD, et al. Prognosis research strategy (PROGRESS) 4: Stratified medicine research. BMJ 2013; 346:e5793
20. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: A framework for researching clinical outcomes. BMJ 2013; 346:e5595
21. Monaghan H, Wells AU, Colby TV, et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest 2004; 125:522-526
22. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168:531-537
23. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35:830-836
24. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184:459-466
25. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012; 67:407-411
26. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: Test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184:1382-1389
27. Corte TJ, Copley SJ, Desai SR, et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39:661-668
28. Ley B, Collard HR. Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:6-7
29. Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573-579
30. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317-1326
31. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68:436-441
32. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-1512
33. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45:613-620
34. Noth I, Zhang Y, Ma S-F, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. Lancet 2013; 1:309-317
35. Zhu L, Wang L, Luo X, et al. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-beta signaling pathway. J Biol Chem 2012; 287:39653-39663
36. Tomita T, Iwatsubo T. Structural biology of presenilins and signal peptide peptidases. J Biol Chem 2013; 288:14673-14680
37. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PloS One 2009; 4:e513
38. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173:188-198
39. Milosevic J, Pandit K, Magister M, et al. Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol 2012; 47:879-887
40. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186:525-535
41. Dakhlallah D, Batte K, Wang Y, et al. Epigenetic regulation of miR-17-92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187:397-405
42. Yang IV, Luna LG, Cotter J, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PloS One 2012; 7:e37708
43. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11:164-168
44. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:717-723
45. Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002; 19:439-446
46. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588-594
47. Naik PK, Bozyk PD, Bentley JK, et al. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 303:L1046-L1056
48. Reilkoff RA, Peng H, Murray LA, et al. Semaphorin 7a regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187:180-188
49. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5:e93
50. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76
51. Maher TM. PROFILEing idiopathic pulmonary fibrosis: Rethinking biomarker discovery. Eur Respir Rev 2013; 22:148-152
52. Huie TJ, Moss M, Frankel SK. What can biomarkers tell us about the pathogenesis of acute exacerbations of idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 2010; 299:L1-2
53. Guenther A, European IPFN. The European IPF Network: Towards better care for a dreadful disease. Eur Respir J 2011; 37:747-748